HSA | FSA CARDS ARE NOW ACCEPTED

This article is part of the PlexusDx Education Hub — your resource for evidence-based guidance on GLP-1 therapies, weight management protocols, and the genetic variables that shape every metabolic decision. Browse all Peptides & GLP-1 education

Novo Nordisk is one of the two largest manufacturers in the GLP-1 receptor agonist landscape as of April 2026. This article covers Novo Nordisk's GLP-1 product portfolio, the FDA-approved indications, and how its products fit against the broader competitive landscape — plus the genetic variables that sit upstream of every GLP-1 pathway compound regardless of manufacturer.

Novo Nordisk's GLP-1 portfolio

Novo Nordisk markets Ozempic (semaglutide, FDA-approved for type 2 diabetes in 2017), Wegovy (semaglutide 2.4 mg, FDA-approved for chronic weight management in 2021), Rybelsus (oral semaglutide, FDA-approved for type 2 diabetes in 2019), Victoza (liraglutide, FDA-approved for type 2 diabetes in 2010 with a 2017 cardiovascular indication), and Saxenda (liraglutide 3 mg, FDA-approved for chronic weight management in 2014). Pipeline includes emerging obesity agents such as CagriSema (cagrilintide + semaglutide combination).

How Novo Nordisk's products compare to Eli Lilly

The two companies dominate the GLP-1 receptor agonist landscape with distinct molecular strategies: Novo Nordisk focuses on GLP-1-selective compounds (semaglutide, liraglutide); Eli Lilly markets the only FDA-approved GIP/GLP-1 dual agonist (tirzepatide) and has a GLP-1-selective option as well (dulaglutide). Head-to-head trials (SURPASS-2: tirzepatide vs semaglutide 1 mg in type 2 diabetes; SUSTAIN 7: semaglutide vs dulaglutide) inform the competitive picture, though direct weight-management head-to-head data is limited.

Cost positioning

Manufacturer list prices are broadly similar across branded products — typically $800–$1,600 per month at U.S. list as of April 2026. Manufacturer savings card programs differ by product. Patient assistance programs exist at both companies for eligible uninsured or underinsured patients. Compounded alternatives through 503A pharmacies are priced separately.

Shared safety profile

All FDA-approved GLP-1 receptor agonists and GIP/GLP-1 dual agonists across both manufacturers carry the class boxed warning for thyroid C-cell tumor risk observed in rodent studies, and are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Common side effects are gastrointestinal. Rare serious events include pancreatitis, gallbladder events, and acute kidney injury in the context of dehydration.

PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols — available as Semaglutide Injection, Semaglutide Oral, Tirzepatide Injection, and Tirzepatide Oral. What sets the PlexusDx approach apart is the upstream genetic context. Before starting any GLP-1 pathway protocol, the Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, and 150+ genetic insights — including variants in FTO, GLP1R, MC4R that shape your baseline GLP-1, appetite-regulation, and energy-balance biology. Knowing that genetic profile alongside the protocol itself is the test before you invest approach — turning guesswork into an informed conversation with your healthcare provider.

Related reading on PlexusDx: Ozempic Cost, Ozempic for Diabetes, Ozempic for Weight Loss, Ozempic Price.

Disclaimer: This article is educational. PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols — this article covers the mechanism, evidence, and genetic context that informs any decision to use them. PlexusDx does not sell, prescribe, or recommend any other therapeutic peptide in the GLP-1 category beyond semaglutide and tirzepatide (including dulaglutide, liraglutide, retatrutide, cagrilintide, and related compounds). The Precision Peptide Genetic Test analyzes how your genes influence peptide-related biological pathways — it does not predict response to any specific medication. Consult a qualified healthcare provider before beginning any peptide protocol.

Start with the biology. Take the Precision Peptide Genetic Test, or explore the Weight Management Protocols.

Frequently Asked Questions

What GLP-1 products does Novo Nordisk make?

Novo Nordisk markets Ozempic (semaglutide for type 2 diabetes), Wegovy (semaglutide 2.4 mg for chronic weight management), Rybelsus (oral semaglutide for type 2 diabetes), Victoza (liraglutide for type 2 diabetes), and Saxenda (liraglutide 3 mg for chronic weight management). Each product has a distinct FDA-approved indication.

Which company makes the most effective GLP-1?

Effectiveness is trial-specific and population-specific. SURPASS-2 (tirzepatide vs semaglutide 1 mg in type 2 diabetes) and SUSTAIN 7 (semaglutide vs dulaglutide 1.5 mg) inform the competitive picture. Direct weight-management head-to-head data is limited across most comparisons. Individual response varies widely — discuss with a healthcare provider who can weigh personal factors.

How do costs compare between Novo Nordisk and Eli Lilly?

Manufacturer list prices are broadly similar — typically $800–$1,600 per month at U.S. list as of April 2026. Savings programs, insurance coverage, and out-of-pocket cost vary more by product, plan, and indication than by manufacturer. Verify current terms at the time of fill.

Does genetic testing predict response to Novo Nordisk products specifically?

No. The Precision Peptide Genetic Test does not predict response to any specific manufacturer's products. It analyzes pathway-level variants in FTO, GLP1R, MC4R, and TCF7L2 that shape baseline GLP-1 and energy-balance biology — the upstream context that applies across both Novo Nordisk and Eli Lilly GLP-1 compounds.

This article is part of the PlexusDx Education Hub. Browse all Peptides & GLP-1 education